Innate Pharma (IPHA, Financial) has announced significant changes to its existing collaboration with Sanofi, originally established in January 2016. Under this updated arrangement, Sanofi has decided to focus on developing SAR’514/IPH6401 for autoimmune conditions according to the terms of the 2016 agreement.
In a strategic realignment, both companies have mutually agreed to end their partnership concerning SAR’579/IPH6101. Consequently, Innate Pharma will reclaim full rights to develop SAR’579/IPH6101 independently.
Part of the revised discussions includes a potential investment by Sanofi, where the pharmaceutical giant may acquire up to EUR 15 million in new shares of Innate Pharma. The specifics of this investment will hinge on prevailing market conditions to determine its scale and pricing.
The agreements pertaining to the 2022 research collaboration between the two companies will remain unchanged amidst these developments.
